Evidence map›Paper›PMID 35894205›Full record

ArticleACS chemical neuroscience2022

New Technologies to Investigate Neuropeptides at Scale.

Tommaso Patriarchi

Abstract read
In one paragraph

Article in ACS chemical neuroscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Tommaso PatriarchiInstitute of Pharmacology and Toxicology and Neuroscience Center Zurich, University of Zürich, Zürich CH-8057, Switzerland.ORCID 0000-0001-9351-3734

Funding

Swiss National Science Foundation 196455
6 · The paper itself

Abstract

Neuropeptides are some of the most elusive molecules to monitor in neuroscience. Detecting their release and spread in brain tissue requires the development and use of advanced technologies that enable specific neuropeptide measurements with high spatial and temporal resolution. This Viewpoint highlights some of the emerging tools and techniques that are already advancing our knowledge of neuropeptide physiology and discusses possible future developments.

Indexed as

NeuropeptidesNeurosciencesBrainNeuropeptidesfluorescent proteinsG-protein coupled receptorsimagingNeuropeptidesoptogenetics

Identifiers

PMID35894205
PMCPMC7613611

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.